Supplemental Material2 - Supplemental material for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
Luisa Guidi
Daniela Pugliese
Tommaso Panici Tonucci
Lorenzo Bertani
Francesco Costa
Giuseppe Privitera
Barbara Tolusso
Clara Di Mario
Eleonora Albano
Gherardo Tapete
Elisa Gremese
Alfredo Papa
Antonio Gasbarrini
Gian Ludovico Rapaccini
Alessandro Armuzzi
10.25384/SAGE.9767369.v1
https://sage.figshare.com/articles/journal_contribution/Supplemental_Material2_-_Supplemental_material_for_Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/9767369
<p>Supplemental material, Supplemental Material2 for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease by Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Barbara Tolusso, Clara Di Mario, Eleonora Albano, Gherardo Tapete, Elisa Gremese, Alfredo Papa, Antonio Gasbarrini, Gian Ludovico Rapaccini and Alessandro Armuzzi in United European Gastroenterology Journal</p>
2019-09-04 12:08:15
Vedolizumab
therapeutic drug monitoring
Crohn’s disease
ulcerative colitis